- Home
- BRAG vs CUE Comparison
BRAG vs CUE Comparison
Compare BRAG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- CUE
- Stock Information
- Founded
- BRAG 2018
- CUE 2014
- Country
- BRAG Canada
- CUE United States
- Employees
- BRAG N/A
- CUE N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BRAG Technology
- CUE Health Care
- Exchange
- BRAG Nasdaq
- CUE Nasdaq
- Market Cap
- BRAG 123.3M
- CUE 91.9M
- IPO Year
- BRAG N/A
- CUE 2018
- Fundamental
- Price
- BRAG $5.44
- CUE $1.44
- Analyst Decision
- BRAG Buy
- CUE Strong Buy
- Analyst Count
- BRAG 3
- CUE 5
- Target Price
- BRAG $6.67
- CUE $5.00
- AVG Volume (30 Days)
- BRAG 81.3K
- CUE 396.9K
- Earning Date
- BRAG 03-25-2025
- CUE 03-10-2025
- Dividend Yield
- BRAG N/A
- CUE N/A
- EPS Growth
- BRAG N/A
- CUE N/A
- EPS
- BRAG N/A
- CUE N/A
- Revenue
- BRAG $109,522,641.00
- CUE $9,532,000.00
- Revenue This Year
- BRAG $11.40
- CUE $73.11
- Revenue Next Year
- BRAG $10.75
- CUE $11.02
- P/E Ratio
- BRAG N/A
- CUE N/A
- Revenue Growth
- BRAG 4.64
- CUE 149.53
- 52 Week Low
- BRAG $2.86
- CUE $0.45
- 52 Week High
- BRAG $7.00
- CUE $2.58
- Technical
- Relative Strength Index (RSI)
- BRAG 77.02
- CUE 54.92
- Support Level
- BRAG $4.70
- CUE $1.27
- Resistance Level
- BRAG $5.10
- CUE $1.45
- Average True Range (ATR)
- BRAG 0.27
- CUE 0.13
- MACD
- BRAG 0.12
- CUE 0.00
- Stochastic Oscillator
- BRAG 90.96
- CUE 77.86
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.